Loading…
Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease
The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ) induction in SH-SY5Y cells at a range of con...
Saved in:
Published in: | Experimental and therapeutic medicine 2019-05, Vol.17 (5), p.3755-3767 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3 |
container_end_page | 3767 |
container_issue | 5 |
container_start_page | 3755 |
container_title | Experimental and therapeutic medicine |
container_volume | 17 |
creator | Ji, Shiliang Li, Shanshan Zhao, Xingxing Kang, Naixin Cao, Keke Zhu, Yingying Peng, Panpan Fan, Jing Xu, Qiongming Yang, Shilin Liu, Yanli |
description | The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ)
induction in SH-SY5Y cells at a range of concentrations. Their effects on cell viability and reactive oxygen species (ROS) were determined by performing MTT and dichlorofluorescin diacetate assays, respectively. The concentration of intracellular Ca
was determined using Fluo-3AM to stain SH-SY5Y cells. SA and TB treatments were also assessed in Aβ
-induced mice. Y-maze and Morris water maze methods were utilized to assess murine learning and memory capability. The pathological changes of murine hippocampi was determined using H&E and Nissl staining. In addition, biochemical parameters associated with intracellular reactive oxygen pathways including Maleic dialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), acetylcholinesterase (AChE) and Calnexin were also assessed. TB and SA treatment in Aβ
-induced SH-SY5Y cells resulted in the restoration of cell morphology, an increase of SOD and GSH-Px activity, a decrease in ROS, Ca
and MDA content, and a decrease in Calnexin expression. Furthermore, SA or TB treatment administered to Aβ
-induced mice improved their spatial/non-spatial learning and memory capabilities. The efficacy of treatment was also supported by a marked change in the morphological structure of pyramidal neurons in the CA1 areas of murine hippocampi, as well as an increase of SOD and GSH-Px activity. Treatment also resulted in a decrease in MDA content, AchE activity and Calnexin expression in murine hippocampal tissue. As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Aβ
via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development. |
doi_str_mv | 10.3892/etm.2019.7355 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A585448703</galeid><sourcerecordid>A585448703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3</originalsourceid><addsrcrecordid>eNptksFvFCEUxidGY5vao1dD4kEPnRUGGJiLydpoa9JEE-uZsPDYpWFghdlN1r9edrtWa4QD7z1-7yOPfE3zkuAZlUP3DqZx1mEyzATl_ElzSsTQtQQT_vQY40GSk-a8lDtcF--JlPx5c0JrXYqenDbma04TmMlvAeUUACWH1iuIuwDTSsfkLVqGnUnFWygX6DZliIcEfUA6WvRNb_XkD4X5BfIRzcPPFfgR8puCrC-gC7xonjkdCpwfz7Pm-6ePt5fX7c2Xq8-X85vWMNJNLWMGYwvWMescNQByqJnBone9Ae2slY5x3S-wqTNzQik4XQMnFkI7WNCz5v297nqzGGsnxCnroNbZjzrvVNJePb6JfqWWaat6xoTo-yrw9iiQ048NlEmNvhgIQUdIm6K6juCOE0Z5RV__g96lTY51vAMl6VB_-w-11AGUjy7Vd81eVM255IxJgWmlZv-h6rYwepMiOF_rjxra-waTUykZ3MOMBKu9MVQ1htobQ-2NUflXf3_MA_3bBvQXeTC00Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2210839056</pqid></control><display><type>article</type><title>Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease</title><source>PubMed Central</source><creator>Ji, Shiliang ; Li, Shanshan ; Zhao, Xingxing ; Kang, Naixin ; Cao, Keke ; Zhu, Yingying ; Peng, Panpan ; Fan, Jing ; Xu, Qiongming ; Yang, Shilin ; Liu, Yanli</creator><creatorcontrib>Ji, Shiliang ; Li, Shanshan ; Zhao, Xingxing ; Kang, Naixin ; Cao, Keke ; Zhu, Yingying ; Peng, Panpan ; Fan, Jing ; Xu, Qiongming ; Yang, Shilin ; Liu, Yanli</creatorcontrib><description>The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ)
induction in SH-SY5Y cells at a range of concentrations. Their effects on cell viability and reactive oxygen species (ROS) were determined by performing MTT and dichlorofluorescin diacetate assays, respectively. The concentration of intracellular Ca
was determined using Fluo-3AM to stain SH-SY5Y cells. SA and TB treatments were also assessed in Aβ
-induced mice. Y-maze and Morris water maze methods were utilized to assess murine learning and memory capability. The pathological changes of murine hippocampi was determined using H&E and Nissl staining. In addition, biochemical parameters associated with intracellular reactive oxygen pathways including Maleic dialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), acetylcholinesterase (AChE) and Calnexin were also assessed. TB and SA treatment in Aβ
-induced SH-SY5Y cells resulted in the restoration of cell morphology, an increase of SOD and GSH-Px activity, a decrease in ROS, Ca
and MDA content, and a decrease in Calnexin expression. Furthermore, SA or TB treatment administered to Aβ
-induced mice improved their spatial/non-spatial learning and memory capabilities. The efficacy of treatment was also supported by a marked change in the morphological structure of pyramidal neurons in the CA1 areas of murine hippocampi, as well as an increase of SOD and GSH-Px activity. Treatment also resulted in a decrease in MDA content, AchE activity and Calnexin expression in murine hippocampal tissue. As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Aβ
via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2019.7355</identifier><identifier>PMID: 30988761</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Advertising executives ; Alzheimer's disease ; Analysis ; Brain ; Care and treatment ; Dementia ; Development and progression ; Diagnosis ; Glycosides ; Health aspects ; Homeostasis ; Laboratory animals ; Medical research ; Neurons ; Oxidative stress ; Pathogenesis ; Peptides ; Peroxidase ; Plant extracts ; Prevention ; Reactive oxygen species ; Studies ; Superoxides ; Treatment outcome ; Tuberculosis</subject><ispartof>Experimental and therapeutic medicine, 2019-05, Vol.17 (5), p.3755-3767</ispartof><rights>COPYRIGHT 2019 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright © 2019, Spandidos Publications 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3</citedby><cites>FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447766/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447766/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30988761$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ji, Shiliang</creatorcontrib><creatorcontrib>Li, Shanshan</creatorcontrib><creatorcontrib>Zhao, Xingxing</creatorcontrib><creatorcontrib>Kang, Naixin</creatorcontrib><creatorcontrib>Cao, Keke</creatorcontrib><creatorcontrib>Zhu, Yingying</creatorcontrib><creatorcontrib>Peng, Panpan</creatorcontrib><creatorcontrib>Fan, Jing</creatorcontrib><creatorcontrib>Xu, Qiongming</creatorcontrib><creatorcontrib>Yang, Shilin</creatorcontrib><creatorcontrib>Liu, Yanli</creatorcontrib><title>Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ)
induction in SH-SY5Y cells at a range of concentrations. Their effects on cell viability and reactive oxygen species (ROS) were determined by performing MTT and dichlorofluorescin diacetate assays, respectively. The concentration of intracellular Ca
was determined using Fluo-3AM to stain SH-SY5Y cells. SA and TB treatments were also assessed in Aβ
-induced mice. Y-maze and Morris water maze methods were utilized to assess murine learning and memory capability. The pathological changes of murine hippocampi was determined using H&E and Nissl staining. In addition, biochemical parameters associated with intracellular reactive oxygen pathways including Maleic dialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), acetylcholinesterase (AChE) and Calnexin were also assessed. TB and SA treatment in Aβ
-induced SH-SY5Y cells resulted in the restoration of cell morphology, an increase of SOD and GSH-Px activity, a decrease in ROS, Ca
and MDA content, and a decrease in Calnexin expression. Furthermore, SA or TB treatment administered to Aβ
-induced mice improved their spatial/non-spatial learning and memory capabilities. The efficacy of treatment was also supported by a marked change in the morphological structure of pyramidal neurons in the CA1 areas of murine hippocampi, as well as an increase of SOD and GSH-Px activity. Treatment also resulted in a decrease in MDA content, AchE activity and Calnexin expression in murine hippocampal tissue. As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Aβ
via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development.</description><subject>Advertising executives</subject><subject>Alzheimer's disease</subject><subject>Analysis</subject><subject>Brain</subject><subject>Care and treatment</subject><subject>Dementia</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Glycosides</subject><subject>Health aspects</subject><subject>Homeostasis</subject><subject>Laboratory animals</subject><subject>Medical research</subject><subject>Neurons</subject><subject>Oxidative stress</subject><subject>Pathogenesis</subject><subject>Peptides</subject><subject>Peroxidase</subject><subject>Plant extracts</subject><subject>Prevention</subject><subject>Reactive oxygen species</subject><subject>Studies</subject><subject>Superoxides</subject><subject>Treatment outcome</subject><subject>Tuberculosis</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNptksFvFCEUxidGY5vao1dD4kEPnRUGGJiLydpoa9JEE-uZsPDYpWFghdlN1r9edrtWa4QD7z1-7yOPfE3zkuAZlUP3DqZx1mEyzATl_ElzSsTQtQQT_vQY40GSk-a8lDtcF--JlPx5c0JrXYqenDbma04TmMlvAeUUACWH1iuIuwDTSsfkLVqGnUnFWygX6DZliIcEfUA6WvRNb_XkD4X5BfIRzcPPFfgR8puCrC-gC7xonjkdCpwfz7Pm-6ePt5fX7c2Xq8-X85vWMNJNLWMGYwvWMescNQByqJnBone9Ae2slY5x3S-wqTNzQik4XQMnFkI7WNCz5v297nqzGGsnxCnroNbZjzrvVNJePb6JfqWWaat6xoTo-yrw9iiQ048NlEmNvhgIQUdIm6K6juCOE0Z5RV__g96lTY51vAMl6VB_-w-11AGUjy7Vd81eVM255IxJgWmlZv-h6rYwepMiOF_rjxra-waTUykZ3MOMBKu9MVQ1htobQ-2NUflXf3_MA_3bBvQXeTC00Q</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Ji, Shiliang</creator><creator>Li, Shanshan</creator><creator>Zhao, Xingxing</creator><creator>Kang, Naixin</creator><creator>Cao, Keke</creator><creator>Zhu, Yingying</creator><creator>Peng, Panpan</creator><creator>Fan, Jing</creator><creator>Xu, Qiongming</creator><creator>Yang, Shilin</creator><creator>Liu, Yanli</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190501</creationdate><title>Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease</title><author>Ji, Shiliang ; Li, Shanshan ; Zhao, Xingxing ; Kang, Naixin ; Cao, Keke ; Zhu, Yingying ; Peng, Panpan ; Fan, Jing ; Xu, Qiongming ; Yang, Shilin ; Liu, Yanli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Advertising executives</topic><topic>Alzheimer's disease</topic><topic>Analysis</topic><topic>Brain</topic><topic>Care and treatment</topic><topic>Dementia</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Glycosides</topic><topic>Health aspects</topic><topic>Homeostasis</topic><topic>Laboratory animals</topic><topic>Medical research</topic><topic>Neurons</topic><topic>Oxidative stress</topic><topic>Pathogenesis</topic><topic>Peptides</topic><topic>Peroxidase</topic><topic>Plant extracts</topic><topic>Prevention</topic><topic>Reactive oxygen species</topic><topic>Studies</topic><topic>Superoxides</topic><topic>Treatment outcome</topic><topic>Tuberculosis</topic><toplevel>online_resources</toplevel><creatorcontrib>Ji, Shiliang</creatorcontrib><creatorcontrib>Li, Shanshan</creatorcontrib><creatorcontrib>Zhao, Xingxing</creatorcontrib><creatorcontrib>Kang, Naixin</creatorcontrib><creatorcontrib>Cao, Keke</creatorcontrib><creatorcontrib>Zhu, Yingying</creatorcontrib><creatorcontrib>Peng, Panpan</creatorcontrib><creatorcontrib>Fan, Jing</creatorcontrib><creatorcontrib>Xu, Qiongming</creatorcontrib><creatorcontrib>Yang, Shilin</creatorcontrib><creatorcontrib>Liu, Yanli</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ji, Shiliang</au><au>Li, Shanshan</au><au>Zhao, Xingxing</au><au>Kang, Naixin</au><au>Cao, Keke</au><au>Zhu, Yingying</au><au>Peng, Panpan</au><au>Fan, Jing</au><au>Xu, Qiongming</au><au>Yang, Shilin</au><au>Liu, Yanli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>17</volume><issue>5</issue><spage>3755</spage><epage>3767</epage><pages>3755-3767</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ)
induction in SH-SY5Y cells at a range of concentrations. Their effects on cell viability and reactive oxygen species (ROS) were determined by performing MTT and dichlorofluorescin diacetate assays, respectively. The concentration of intracellular Ca
was determined using Fluo-3AM to stain SH-SY5Y cells. SA and TB treatments were also assessed in Aβ
-induced mice. Y-maze and Morris water maze methods were utilized to assess murine learning and memory capability. The pathological changes of murine hippocampi was determined using H&E and Nissl staining. In addition, biochemical parameters associated with intracellular reactive oxygen pathways including Maleic dialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), acetylcholinesterase (AChE) and Calnexin were also assessed. TB and SA treatment in Aβ
-induced SH-SY5Y cells resulted in the restoration of cell morphology, an increase of SOD and GSH-Px activity, a decrease in ROS, Ca
and MDA content, and a decrease in Calnexin expression. Furthermore, SA or TB treatment administered to Aβ
-induced mice improved their spatial/non-spatial learning and memory capabilities. The efficacy of treatment was also supported by a marked change in the morphological structure of pyramidal neurons in the CA1 areas of murine hippocampi, as well as an increase of SOD and GSH-Px activity. Treatment also resulted in a decrease in MDA content, AchE activity and Calnexin expression in murine hippocampal tissue. As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Aβ
via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>30988761</pmid><doi>10.3892/etm.2019.7355</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1792-0981 |
ispartof | Experimental and therapeutic medicine, 2019-05, Vol.17 (5), p.3755-3767 |
issn | 1792-0981 1792-1015 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447766 |
source | PubMed Central |
subjects | Advertising executives Alzheimer's disease Analysis Brain Care and treatment Dementia Development and progression Diagnosis Glycosides Health aspects Homeostasis Laboratory animals Medical research Neurons Oxidative stress Pathogenesis Peptides Peroxidase Plant extracts Prevention Reactive oxygen species Studies Superoxides Treatment outcome Tuberculosis |
title | Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T07%3A48%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20role%20of%20phenylethanoid%20glycosides,%20Torenoside%20B%20and%20Savatiside%20A,%20in%20Alzheimer's%20disease&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Ji,%20Shiliang&rft.date=2019-05-01&rft.volume=17&rft.issue=5&rft.spage=3755&rft.epage=3767&rft.pages=3755-3767&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2019.7355&rft_dat=%3Cgale_pubme%3EA585448703%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-44c00dedf4dff3cee89dedc076f6ceafdd8f45a6b0c2015133efa015f7b7afeb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2210839056&rft_id=info:pmid/30988761&rft_galeid=A585448703&rfr_iscdi=true |